283 related articles for article (PubMed ID: 34025586)
21. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
[TBL] [Abstract][Full Text] [Related]
22. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
23. IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands.
Maione L; Albrici C; Grunenwald S; Mouly C; Cimino V; Lecoq AL; Souberbielle JC; Caron P; Chanson P
J Clin Endocrinol Metab; 2022 Aug; 107(9):e3644-e3653. PubMed ID: 35772775
[TBL] [Abstract][Full Text] [Related]
24. T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective.
Potorac I; Beckers A; Bonneville JF
Pituitary; 2017 Feb; 20(1):116-120. PubMed ID: 28197813
[TBL] [Abstract][Full Text] [Related]
25. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy.
Annamalai AK; Webb A; Kandasamy N; Elkhawad M; Moir S; Khan F; Maki-Petaja K; Gayton EL; Strey CH; O'Toole S; Ariyaratnam S; Halsall DJ; Chaudhry AN; Berman L; Scoffings DJ; Antoun NM; Dutka DP; Wilkinson IB; Shneerson JM; Pickard JD; Simpson HL; Gurnell M
J Clin Endocrinol Metab; 2013 Mar; 98(3):1040-50. PubMed ID: 23393175
[TBL] [Abstract][Full Text] [Related]
26. Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs.
Corica G; Pirchio R; Milioto A; Nista F; Arecco A; Mattioli L; Auriemma RS; Cocchiara F; Pivonello R; Colao A; Ferone D; Gatto F
J Endocrinol Invest; 2024 Mar; 47(3):683-697. PubMed ID: 37695461
[TBL] [Abstract][Full Text] [Related]
27. Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice.
Geer EB; Sisco J; Adelman DT; Ludlam WH; Haviv A; Liu S; Mathias SD; Gelbaum D; Shi L
BMC Endocr Disord; 2020 Jul; 20(1):117. PubMed ID: 32736547
[TBL] [Abstract][Full Text] [Related]
28. Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs.
Chiloiro S; Giampietro A; Frara S; Bima C; Donfrancesco F; Fleseriu CM; Pontecorvi A; Giustina A; Fleseriu M; De Marinis L; Bianchi A
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31613969
[TBL] [Abstract][Full Text] [Related]
29. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
[TBL] [Abstract][Full Text] [Related]
31. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study.
Petersenn S; Houchard A; Sert C; Caron PJ;
Pituitary; 2020 Apr; 23(2):171-181. PubMed ID: 31879842
[TBL] [Abstract][Full Text] [Related]
32. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
Giustina A; Mazziotti G; Cannavò S; Castello R; Arnaldi G; Bugari G; Cozzi R; Ferone D; Formenti AM; Gatti E; Grottoli S; Maffei P; Maffezzoni F; Montini M; Terzolo M; Ghigo E
J Clin Endocrinol Metab; 2017 Jul; 102(7):2454-2464. PubMed ID: 28419317
[TBL] [Abstract][Full Text] [Related]
33. Survivin: A Potential Marker of Resistance to Somatostatin Receptor Ligands.
Herkenhoff CGB; Trarbach EB; Batista RL; Soares IC; Frassetto FP; do Nascimento FBP; Grande IPP; Silva PPB; Duarte FHG; Bronstein MD; Jallad RS
J Clin Endocrinol Metab; 2023 Mar; 108(4):876-887. PubMed ID: 36273993
[TBL] [Abstract][Full Text] [Related]
34. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
35. Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy.
Bona C; Prencipe N; Berton AM; Bioletto F; Parasiliti-Caprino M; Gasco V; Ghigo E; Grottoli S
J Endocrinol Invest; 2022 Oct; 45(10):1955-1965. PubMed ID: 35748978
[TBL] [Abstract][Full Text] [Related]
36. Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain.
Biagetti B; Iglesias P; Villar-Taibo R; Moure MD; Paja M; Araujo-Castro M; Ares J; Álvarez-Escola C; Vicente A; Álvarez Guivernau È; Novoa-Testa I; Guerrero Perez F; Cámara R; Lecumberri B; García Gómez C; Bernabéu I; Manjón L; Gaztambide S; Cordido F; Webb SM; Menéndez-Torre EL; Díez JJ; Simó R; Puig-Domingo M
Front Endocrinol (Lausanne); 2022; 13():984877. PubMed ID: 36187107
[TBL] [Abstract][Full Text] [Related]
37. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands.
Kasuki L; Dalmolin MD; Wildemberg LE; Gadelha MR
Clin Endocrinol (Oxf); 2018 Jun; 88(6):889-895. PubMed ID: 29520805
[TBL] [Abstract][Full Text] [Related]
38. Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.
Gadelha M; Marques NV; Fialho C; Scaf C; Lamback E; Antunes X; Santos E; Magalhães J; Wildemberg LE
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1571-e1579. PubMed ID: 37357993
[TBL] [Abstract][Full Text] [Related]
39. COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL.
Imani M; Khamseh ME; Asadi P; Ghorbani M; Akbari H; Alaei-Shahmiri F; Honardoost M; Kaynama MR; Malek M
Endocr Pract; 2018 Jun; 24(6):542-547. PubMed ID: 29949429
[TBL] [Abstract][Full Text] [Related]
40. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
